Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88


FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report.

Mehta PA, Gerbing RB, Alonzo TA, Elliott JS, Zamzow TA, Combs M, Stover E, Ross JA, Perentesis JP, Meschinchi S, Lange BJ, Davies SM.

Clin Cancer Res. 2008 Dec 1;14(23):7896-9. doi: 10.1158/1078-0432.CCR-08-0418.


MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.

Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM.

Pediatr Blood Cancer. 2010 Aug;55(2):248-53. doi: 10.1002/pbc.22519.


XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report.

Mehta PA, Alonzo TA, Gerbing RB, Elliott JS, Wilke TA, Kennedy RJ, Ross JA, Perentesis JP, Lange BJ, Davies SM; Children's Oncology Group.

Blood. 2006 Jan 1;107(1):39-45. Epub 2005 Sep 8.


Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children's Oncology Group.

Johnston DL, Alonzo TA, Gerbing RB, Hirsch B, Heerema NA, Ravindranath Y, Woods WG, Lange BJ, Gamis AS, Raimondi SC.

Pediatr Blood Cancer. 2013 Dec;60(12):2073-8. doi: 10.1002/pbc.24573. Epub 2013 Aug 30.


BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Moore AS, Alonzo TA, Gerbing RB, Lange BJ, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S.

Pediatr Blood Cancer. 2014 Apr;61(4):647-52. doi: 10.1002/pbc.24822. Epub 2013 Oct 11.


Influence of BCL2-938C>A and BAX-248G>A promoter polymorphisms in the development of AML: case-control study from South India.

Cingeetham A, Vuree S, Dunna NR, Gorre M, Nanchari SR, Edathara PM, Meka P, Annamaneni S, Digumarthi R, Sinha S, Satti V.

Tumour Biol. 2015 Sep;36(10):7967-76. doi: 10.1007/s13277-015-3457-4. Epub 2015 May 10.


Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.

Falk IJ, Fyrberg A, Paul E, Nahi H, Hermanson M, Rosenquist R, Höglund M, Palmqvist L, Stockelberg D, Wei Y, Gréen H, Lotfi K.

Am J Hematol. 2013 Dec;88(12):1001-6. doi: 10.1002/ajh.23549. Epub 2013 Sep 9.


WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group.

Ho PA, Kuhn J, Gerbing RB, Pollard JA, Zeng R, Miller KL, Heerema NA, Raimondi SC, Hirsch BA, Franklin JL, Lange B, Gamis AS, Alonzo TA, Meshinchi S.

J Clin Oncol. 2011 Feb 20;29(6):704-11. doi: 10.1200/JCO.2010.31.9327. Epub 2010 Dec 28.


Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia.

Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM.

Br J Haematol. 2009 Feb;144(3):388-94. doi: 10.1111/j.1365-2141.2008.07461.x. Epub 2008 Nov 22.


Assessment of bcl-2 expression as modulator of fas mediated apoptosis in acute leukemia.

Aref S, Salama O, Al-Tonbary Y, Mansour A.

Hematology. 2004 Apr;9(2):113-21.


The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group.

Ho PA, Alonzo TA, Gerbing RB, Kuhn J, Pollard JA, Hirsch B, Raimondi SC, Gamis AS, Meshinchi S.

Pediatr Blood Cancer. 2014 Jan;61(1):81-8. doi: 10.1002/pbc.24700. Epub 2013 Aug 16.


Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission.

Mao C, Fu XH, Yuan JQ, Yang ZY, Huang YF, Ye QL, Wu XY, Hu XF, Zhai ZM, Tang JL.

Cochrane Database Syst Rev. 2015 Nov 6;(11):CD010248. doi: 10.1002/14651858.CD010248.pub2. Review.


Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.

Ravindranath Y, Chang M, Steuber CP, Becton D, Dahl G, Civin C, Camitta B, Carroll A, Raimondi SC, Weinstein HJ; Pediatric Oncology Group.

Leukemia. 2005 Dec;19(12):2101-16.


Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia.

Farre L, Bittencourt AL, Silva-Santos G, Almeida A, Silva AC, Decanine D, Soares GM, Alcantara LC Jr, Van Dooren S, Galvão-Castro B, Vandamme AM, Van Weyenbergh J.

J Leukoc Biol. 2008 Jan;83(1):220-2. Epub 2007 Oct 25.


Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome.

Tourneur L, Delluc S, Lévy V, Valensi F, Radford-Weiss I, Legrand O, Vargaftig J, Boix C, Macintyre EA, Varet B, Chiocchia G, Buzyn A.

Cancer Res. 2004 Nov 1;64(21):8101-8.


A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia.

Sunter NJ, Scott K, Hills R, Grimwade D, Taylor S, Worrillow LJ, Fordham SE, Forster VJ, Jackson G, Bomken S, Jones G, Allan JM.

Blood. 2012 Jan 5;119(1):196-205. doi: 10.1182/blood-2011-04-349803. Epub 2011 Nov 14.


Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891.

Lange BJ, Kobrinsky N, Barnard DR, Arthur DC, Buckley JD, Howells WB, Gold S, Sanders J, Neudorf S, Smith FO, Woods WG.

Blood. 1998 Jan 15;91(2):608-15.


High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia.

Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F, Karawajew L, Ludwig WD, Wuchter C.

Clin Cancer Res. 2004 Jun 1;10(11):3737-44.


Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia.

Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, Skibola CF, Smith MT, Morgan GJ.

Cancer Res. 2003 Aug 1;63(15):4327-30.


Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.

Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T.

J Clin Oncol. 2004 Nov 1;22(21):4384-93.


Supplemental Content

Support Center